Kymera Results Presentation Deck

● First two dose levels completed PK and PD profiles in DL1 and DL2 consistent with preclinical data supporting once every three-week dosing regimen Up to 95/100% KD of Ikaros/Aiolos and 40% KD of IRAK4 in blood Consistent degradation in blood and tumor At least 72h target degradation observed, a profile that in preclinical species led to robust antitumor activity in MYD88 mutant tumors ● ● Demonstration of Initial POM for KT-413 ● First 2 dose levels generally well-tolerated with no DLTs, treatment-related SAEs or neutropenia observed DL3 currently enrolling patients DL3/4 expected to be clinically active doses KYMERA ©2022 KYMERA THERAPEUTICS, INC. PAGE 22

View entire presentation